Novartis is mirroring its approach to pharma R&D and leveraging the side products of its biomarker work there to build a commercial molecular diagnostics franchise. The head of the unit talks about it
Novel molecular tests promise a healthier future for women—and the diagnostic makers who invest in them. Mention "women's health" and you're likely to elicit either a yawn or a groan of protest. Not t
Although it's still a small portion of the $30-plus-billion diagnostic services and test supplies business, molecular diagnostics is on a disproportionately rapid growth curve. Some estimate its reven